Neurology · 2018 · 103 citations · 31 references
Life SciencesNeurosciencePharmacologyMetabolomicsNeurogeneticsPharmacogeneticsClinical MetabolomicsDrug Metabolism GeneticsMovement Disorder GeneticsNeurodegenerative Disease GeneticsParkinson DiseaseParkinsonian DisordersBiomarker DetectionBiomarkers Of Parkinsonian DisordersCaffeine MetabolismDisease Diagnostic BiomarkersLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry AnalysisParkinson Disease BiomarkersReceptor Sensitivity Changes
OBJECTIVE: To investigate the kinetics and metabolism of caffeine in serum from patients with Parkinson disease (PD) and controls using liquid chromatography-mass spectrometry. METHODS: Levels of caffeine and its 11 metabolites in serum from 108 patients with PD and 31 age-matched healthy controls were examined by liquid chromatography-mass spectrometry. Mutations in caffeine-associated genes were screened by direct sequencing. RESULTS: gene encoding adenosine 2A receptor were detected, implying a dissociation of receptor sensitivity changes and phenotype. The profile of serum caffeine and metabolite levels was identified as a potential diagnostic biomarker by receiver operating characteristic curve analysis. CONCLUSION: Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD. This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that decreased serum levels of caffeine and its metabolites identify patients with PD.
31
Gut microbiota are related to Parkinson's disease and clinical phenotype
Filip Scheperjans, Velma T. E. Aho, Pedro A. B. Pereira et al. · Movement Disorders · 2014 · 2K citations · Full text
Colonic bacterial composition in Parkinson's disease
Ali Keshavarzian, Stefan J. Green, Phillip A. Engen et al. · Movement Disorders · 2015 · 1.3K citations